BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25794661)

  • 1. Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas.
    Sebestyén A; Márk Á; Hajdu M; Nagy N; Molnár A; Végső G; Barna G; Kopper L
    Cytokine; 2015 Jun; 73(2):219-24. PubMed ID: 25794661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming Growth Factor β1-induced Apoptosis in Podocytes via the Extracellular Signal-regulated Kinase-Mammalian Target of Rapamycin Complex 1-NADPH Oxidase 4 Axis.
    Das R; Xu S; Nguyen TT; Quan X; Choi SK; Kim SJ; Lee EY; Cha SK; Park KS
    J Biol Chem; 2015 Dec; 290(52):30830-42. PubMed ID: 26565025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.
    Cheng KY; Hao M
    Med Sci Monit; 2017 Apr; 23():2017-2028. PubMed ID: 28446743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of extracellular signal-regulated kinase by TGF-beta1 via TbetaRII and Smad7 dependent mechanisms in human bronchial epithelial BEP2D cells.
    Huo YY; Hu YC; He XR; Wang Y; Song BQ; Zhou PK; Zhu MX; Li G; Wu DC
    Cell Biol Toxicol; 2007 Mar; 23(2):113-28. PubMed ID: 17096210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á
    Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolidase-dependent regulation of TGF β (corrected) and TGF β receptor expressions in human skin fibroblasts.
    Surazynski A; Miltyk W; Prokop I; Palka J
    Eur J Pharmacol; 2010 Dec; 649(1-3):115-9. PubMed ID: 20868675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
    Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
    Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smad signal and TGFbeta induced apoptosis in human lymphoma cells.
    Sebestyén A; Barna G; Nagy K; Jánosi J; Paku S; Kohut E; Berczi L; Mihalik R; Kopper L
    Cytokine; 2005 Jun; 30(5):228-35. PubMed ID: 15927846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of a tumor suppressor PDCD4: Degradation mechanisms of the protein in hepatocellular carcinoma cells.
    Matsuhashi S; Hamajima H; Xia J; Zhang H; Mizuta T; Anzai K; Ozaki I
    Cell Signal; 2014 Mar; 26(3):603-10. PubMed ID: 24334270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β1 inhibits the growth and metastasis of tongue squamous carcinoma cells through Smad4.
    Wang X; Sun W; Zhang C; Ji G; Ge Y; Xu Y; Zhao Y
    Gene; 2011 Oct; 485(2):160-6. PubMed ID: 21726607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
    Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
    Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Chen RH; Su YH; Chuang RL; Chang TY
    Oncogene; 1998 Oct; 17(15):1959-68. PubMed ID: 9788439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells.
    Sebestyén A; Hajdu M; Kis L; Barna G; Kopper L
    Exp Cell Res; 2007 Sep; 313(15):3167-74. PubMed ID: 17643425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DRAK2 participates in a negative feedback loop to control TGF-β/Smads signaling by binding to type I TGF-β receptor.
    Yang KM; Kim W; Bae E; Gim J; Weist BM; Jung Y; Hyun JS; Hernandez JB; Leem SH; Park T; Jeong J; Walsh CM; Kim SJ
    Cell Rep; 2012 Nov; 2(5):1286-99. PubMed ID: 23122956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentiviral-mediated Smad4 RNAi induced anti-proliferation by p16 up-regulation and apoptosis by caspase 3 down-regulation in hepatoma SMMC-7721 cells.
    Huang S; Zhang F; Miao L; Zhang H; Fan Z; Wang X; Ji G
    Oncol Rep; 2008 Nov; 20(5):1053-9. PubMed ID: 18949401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.
    Le Gendre O; Sookdeo A; Duliepre SA; Utter M; Frias M; Foster DA
    Mol Cancer Res; 2013 May; 11(5):474-81. PubMed ID: 23443316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor-β signaling participates in the maintenance of the primordial follicle pool in the mouse ovary.
    Wang ZP; Mu XY; Guo M; Wang YJ; Teng Z; Mao GP; Niu WB; Feng LZ; Zhao LH; Xia GL
    J Biol Chem; 2014 Mar; 289(12):8299-311. PubMed ID: 24515103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.